Large-Scale Study Finds Disease-Modifying Drugs Lead to Fewer MS Hospitalizations | MyMSTeam

Connect with others who understand.

sign up Log in
Resources
About MyMSTeam
Powered By
MULTIPLE SCLEROSIS
NEWS

Large-Scale Study Finds Disease-Modifying Drugs Lead to Fewer MS Hospitalizations

Medically reviewed by Evelyn O. Berman, M.D.
Posted on February 11, 2022

  • A recent study found that disease-modifying drugs (DMDs) reduced hospitalization rates for people with multiple sclerosis (MS) and help long-term in saving on health care costs.
  • DMDs delivered orally or through transfusions were associated with a 29 percent decrease in hospital stays.

The use of disease-modifying drugs for multiple sclerosis can lead to fewer hospital stays and long-term savings on medical expenses, a recent study found. Hospitalization rates were as much as 44 percent lower, depending on the type of DMD a person was taking.

“Our findings provide real-world evidence that will help people living with MS and their doctors make decisions about treatments,” Dr. Huah Shin Ng, a postdoctoral fellow at the University of British Columbia and lead author of the study, told MyMSTeam. “Fewer hospital stays could represent a major health care cost avoidance and lower disease burden for people with MS and their families.”

DMDs are a class of treatments that work to reduce inflammation in people with MS. They can help stave off relapses in people with relapsing forms of the disease, and they may reduce the severity of relapses as well.

For the study, published in Multiple Sclerosis Journal, the research team reviewed data collected over a 22-year period to evaluate the outcomes of more than 35,000 people with MS across four Canadian provinces. In addition, they looked at prescription records to track the use of DMDs for MS, including the type of drug.

Dr. Ng stressed the value of looking at such a large pool of data. “Few regions across the world have access to such comprehensive and population-based health data which can be used to study the benefits and risks of MS drugs in everyday, real-world clinical practice,” Dr. Ng noted.

Although using DMDs did not affect the number of doctor visits that people with MS made, it did reduce hospitalizations. In fact, people with MS on DMDs experienced a 24 percent lower hospitalization rate than people with MS who were not on DMDs, the study found.

Oral or infusion-based DMDs were associated with a 29 percent decrease in hospital stays. However, this number depended on the type of drug. For example, teriflunomide (sold as Aubagio) alone decreased hospitalizations by 18 percent. Another drug, fingolimod (sold as Gilenya), decreased hospitalizations by 44 percent.

The team hypothesized that DMDs may have reduced hospital stays because of their effectiveness in reducing the severity and number of relapses.

Posted on February 11, 2022
All updates must be accompanied by text or a picture.

Become a Subscriber

Get the latest news about multiple sclerosis sent to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Evelyn O. Berman, M.D. is a neurology and pediatric specialist and treats disorders of the brain in children. Review provided by VeriMed Healthcare Network. Learn more about her here
Jocelyn Solis-Moreira is a journalist covering health and science. She received a graduate degree in psychology concentrating on behavioral neuroscience. Learn more about her here

Recent Articles

Meet Dani, Todd, and LaTasha. Real stories from real members.

MyMSTeam Stories: Real Stories From Real Members

Meet Dani, Todd, and LaTasha. Real stories from real members.
Dani works as the music program coordinator at a youth center. Watch this video to see how she fi...

Music and Community: How I Fight MS

Dani works as the music program coordinator at a youth center. Watch this video to see how she fi...
In this video, Dani explains that one of the most important lessons she’s learned since being dia...

How I Learned To Listen to My Body With MS

In this video, Dani explains that one of the most important lessons she’s learned since being dia...
Dani had just started a new job when she was diagnosed with multiple sclerosis.“I had to advocate...

My Advocacy Tips: Taking Care of Future Me With MS

Dani had just started a new job when she was diagnosed with multiple sclerosis.“I had to advocate...
Your race or ethnicity can influence many aspects of your life, including how you’re affected by ...

MS Prevalence by Race and Ethnicity: In the Black Community and More

Your race or ethnicity can influence many aspects of your life, including how you’re affected by ...
Diphenhydramine — sold under many brand names including Benadryl — is a type of antihistamine tha...

Why Is Benadryl Given With Some MS Treatments?

Diphenhydramine — sold under many brand names including Benadryl — is a type of antihistamine tha...
MS News
MS News

Thank you for subscribing!

Become a member to get even more:

sign up for free

close